SMO Clinplus: Announcement regarding the completion of industrial and commercial change registration and issuance of business license.
SMO Clinplus: Legal Opinion of Beijing Guofeng (Shanghai) Law Firm on the 2023 Annual General Meeting of Shareholders of Prius (Shanghai) Pharmaceutical Technology Development Co., Ltd.
SMO Clinplus: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
SMO Clinplus: Prompt Notice on Convening the 2023 Annual General Meeting of Shareholders
SMO Clinplus: Report on the performance of supervisory duties of accounting firms by the Audit Committee of the Board of Directors in 2023
SMO Clinplus: Board of Directors Rules of Procedure (April 2024)
SMO Clinplus: Notice on changing the company's registered capital, amending the “Articles of Association”, and registering industrial and commercial changes
SMO Clinplus: Board Remuneration and Assessment Committee Work Rules (April 2024)
SMO Clinplus: Accounting Services Selection and Employment System (April 2024)
SMO Clinplus: Summary table on the use of non-operating capital and other related capital transactions in 2023
SMO Clinplus: Board Strategy and Sustainability Committee Working Rules (April 2024)
SMO Clinplus: Rules of work for the Audit Committee of the Board of Directors (April 2024)
SMO Clinplus: Rules of Work for the Nomination Committee of the Board of Directors (April 2024)
SMO Clinplus: Announcement on the postponement of some fund-raising projects
SMO Clinplus: Notice on convening the 2023 Annual General Meeting of Shareholders
SMO Clinplus: 2023 Internal Control Self-Assessment Report
SMO Clinplus: Special Report on the 2023 Non-operating Capital Occupation and Other Related Capital Transactions of Prius (Shanghai) Pharmaceutical Technology Development Co., Ltd.
SMO Clinplus: Notice on requesting the shareholders' meeting to authorize the board of directors to issue shares to specific targets through simple procedures
Prius: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Prius: Legal Opinion of Beijing Guofeng (Shanghai) Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Prius (Shanghai) Pharmaceutical Technology Development Co., Ltd.
No Data